Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ambry Genetics Launches FFPE Somatic Variant Profiling Services

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Ambry Genetics announced today that they have launched a somatic variant detection service, developed in collaboration with Illumina.

This service complements Ambry’s extensive menu of next-generation sequencing services and portfolio of diagnostic genetic testing panels for hereditary cancers.

Ambry Genetics has offered next-generation sequencing services since 2007 and has been at the forefront of establishing the technology as a diagnostic tool. Ambry was the first to launch a commercial diagnostic test utilizing next-generation sequencing with their 81 gene XLID panel, as well as the first to offer clinical exome sequencing. Leveraging years of experience, Ambry has developed a somatic cancer panel that can detect the lowest level allele frequency with the highest level of specificity available today.

“Utilizing a novel target enrichment strategy, we are able to detect below 3% minor allele frequency with very high confidence,” said Dr. Aaron Elliott, Director of R&D at Ambry Genetics. “We have optimized every step of the process from QC to bioinformatics to virtually eliminate false positives which are a common problem for FFPE samples in current panels.”

This offering is focused on clinically actionable mutations implicated in solid tumors with a focus on lung, colon, melanoma, gastric and ovarian cancers. The assay covers relevant hotspot regions of 26 genes, including deep sequencing of several genes such as TP53.

“Expanding into somatic mutation detection is a key step to grow our business,” said Ardy Arianpour, Vice President of Business Development at Ambry Genetics. “We have had several top pharmaceutical clients test the product and are extremely happy with the data, we look to further develop the offering and move it into our clinical diagnostics menu this year.”

“Our understanding of cancer is rapidly evolving through a better understanding of genomics. Partnering with leaders in next-generation sequencing services enables us to build better targeted sequencing solutions that fit the needs of service providers,” said Greg Heath, Senior Vice President and General Manager of Illumina’s Diagnostics business. “Bringing services to the clinical research market will help to further evolve our understanding of cancer and ultimately lead to better diagnostic tools.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Symmetry is Key to Collagen
Researchers describe how symmetry may be the key to growing collagen fibres outside the body.
Lose Weight, Escape the Eight: Weight-Based Cancer Risk
IARC has identified eight additional cancer sites linked to overweight and obesity.
Unravelling the Metastatic Mechanism of Melanoma
Research has uncovered the mechanism of melanoma spreading; the findings could lead to a cure for the disease.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Novel MRI Technique Distinguishes Healthy Prostate Tissue from Cancer
The UTSW researchers have determined that glucose stimulates release of the zinc ions from inside epithelial cells, which they could then track on MRIs.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
PARP Proteins Explore Therapeutic Targets in Cancer
Researchers at UTSW have identified a previously unknown role of a certain class of proteins that opens the door to explore therapeutic targets in cancer and other disease.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!